Mechanistically, isorhamnetin inhibits cancer cell proliferation by modulating cyclins and CDKs, promotes apoptosis through caspase activation and mitochondrial dysfunction, and suppresses metastatic spread by downregulating MMPs, VEGF, and key EMT markers. This evidence concerns the gene VEGFA and cancer.